[1]董惠霞,王 茜.非小细胞肺癌患者外周血T淋巴细胞亚群表达及其临床意义[J].医学信息,2023,36(18):136-139.[doi:10.3969/j.issn.1006-1959.2023.18.026]
　DONG Hui-xia,WANG Qian.Expression and Clinical Significance of Peripheral Blood T Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer[J].Journal of Medical Information,2023,36(18):136-139.[doi:10.3969/j.issn.1006-1959.2023.18.026]
点击复制

非小细胞肺癌患者外周血T淋巴细胞亚群表达及其临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年18期
页码:
136-139
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Expression and Clinical Significance of Peripheral Blood T Lymphocyte Subsets in Patients with Non-small Cell Lung Cancer
文章编号:
1006-1959（2023）18-0136-04
作者:
董惠霞; 王 茜
（1.南京市胸科医院检验科，江苏 南京 210029；2.南京医科大学附属脑科医院胸科院区检验科，江苏 南京 210029）
Author(s):
DONG Hui-xia; WANG Qian
(1.Department of Clinical Laboratory,Nanjing Chest Hospital,Nanjing 210029,Jiangsu,China;2.Clinical Laboratory Department of Thoracic Hospital,the Affiliated Nanjing Brain Hospital of Nanjing Medical University,Nanjing 210029,Jiangsu,China)
关键词:
非小细胞肺癌; 肺鳞癌; 肺腺癌; T淋巴细胞亚群
Keywords:
Non-small cell lung cancer; Adenocarcinoma; Squamous cell carcinoma; T lymphocyte subsets
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2023.18.026
文献标志码:
A
摘要:
目的 探索非小细胞肺癌患者外周血T淋巴细胞及其亚群与健康人群的差异，为诊断和治疗非小细胞肺癌提供参考。方法 选取2016年6月-2017年9月我院收治的30例非小细胞肺癌患者（其中腺癌22例，鳞癌8例）作为NSCLC组，另选取20名健康对照者作为健康对照组，比较两组外周血T淋巴细胞及其亚群表达情况。结果 NSCLC组CD3+、CD4+水平、CD4+/CD8+比值低于健康对照组，差异有统计学意义（P＜0.05）；NSCLC组CD8+水平略高于对照组，但差异无统计学意义（P＞0.05）；腺癌和鳞癌患者CD3+、CD4+水平均低于健康对照组，差异有统计学意义（P＜0.05）；鳞癌患者CD4+/CD8+比值低于对照组，差异有统计学意义（P＜0.05）。结论 非小细胞肺癌患者CD3+和CD4+T淋巴细胞水平较健康人低，肺鳞癌CD4+/CD8+比值较健康人低，其细胞免疫功能严重受损。
Abstract:
Objective To explore the difference of peripheral blood T lymphocytes and their subsets between healthy people and non-small cell lung cancer patients, and to provide reference for the diagnosis and treatment of non-small cell lung cancer.Methods A total of 30 patients with non-small cell lung cancer (22 patients with adenocarcinoma, 8 patients with squamous cell carcinoma) admitted to our hospital from June 2016 to September 2017 were selected as the NSCLC group, and 20 healthy controls were selected as the healthy control group. The expression of T lymphocytes and their subsets in peripheral blood was compared between the two groups.Results The levels of CD3+, CD4+ and CD4+/CD8+ in NSCLC group were lower than those in healthy control group, and the differences were statistically significant (P<0.05). The levels of CD3+ and CD4+ in patients with adenocarcinoma and squamous cell carcinoma were lower than those in the healthy control group, and the difference was statistically significant (P<0.05). The ratio of CD4+/CD8+ in patients with squamous cell carcinoma was lower than that in the control group, and the difference was statistically significant (P<0.05).Conclusion The levels of CD3+ and CD4+ T lymphocytes in patients with non-small cell lung cancer are lower than those in healthy people. The CD4+/CD8+ ratio of lung squamous cell carcinoma is lower than that of healthy people, and its cellular immune function is seriously damaged.

参考文献/References:

[1]Sung H,Ferlay J,Siegel RL,et al.Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J].CA Cancer J Clin,2021,71(3):209-249.[2]Hodge G,Barnawi J,Jurisevic C,et al.Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK)T-like and NK cells[J].Clin Exp Immunol,2014,178(1):79-85.[3]Xu L,Chen D,Lu C,et al.Advanced Lung Cancer Is Associated with Decreased Expression of Perforin, CD95, CD38 by Circulating CD3+CD8+ T Lymphocytes[J].Ann Clin Lab Sci,2015,45(5):528-532.[4]牛越,石晓宇.外周血淋巴细胞亚群检测在肺癌患者临床评估及辅助治疗中的意义[J].实用癌症杂志,2019,34(5):785-787.[5]姚斓,王燕嬉,张伟.老年肺癌患者外周血T淋巴细胞亚群和自然杀伤细胞的临床及意义[J].中国老年学杂志,2016,36(4):860-861.[6]柳瑛,王一羽,李林,等.肿瘤患者外周血免疫细胞亚群和有关细胞因子含量的相关性研究[J].现代肿瘤医学,2019,27(7):1132-1134.[7]孙智.四种恶性肿瘤患者外周血T淋巴细胞亚群变化及意义[J].中国药物经济学,2017,12(1):155-157.[8]叶萍.肿瘤患者外周血T淋巴细胞亚群的变化及临床价值分析[J].现代诊断与治疗,2019,30(22):4005-4007.[9]林帝金,刘纯岳,方俊粤,等.乳腺肿瘤患者外周血中T淋巴细胞表面活化分子和Tregs的表达研究[J].现代检验医学杂志,2018,33(5):31-34.[10]Yu DP,Han Y,Zhao QY,et al.CD3+ CD4+ and CD3+ CD8+ lymphocyte subgroups and their surface receptors NKG2D and NKG2A in patients with non-small cell lung cancer[J].Asian Pac J Cancer Prev,2014,15(6):2685-2688.[11]夏欣欣,王慧睿.流式细胞术检测外周血T淋巴细胞亚群的准确性评价[J].包头医学院学报,2018,34(3):5-6.[12]吴姗姗,严峰,邓玉玲,等.小细胞和非小细胞肺癌晚期患者CD3+ CD4+及CD3+ CD8+T淋巴细胞亚群的差异[J].中国免疫学杂志,2015,31(1):114-116.[13]Wang WJ,Tao Z,Gu W,et al.Variation of blood T lymphocyte subgroups in patients with non- small cell lung cancer[J].Asian Pac J Cancer Prev,2013,14(8):4671-4673.[14]李小雪,王鑫,姚舒洋,等.T淋巴细胞亚群水平在晚期肺腺癌治疗中的变化及其临床意义[J].肿瘤研究与临床,2017,29(7):457-459.[15]陈娟,毕明宏,赵论,等.外周血T细胞亚群计数与恶性肿瘤的相关性研究[J].蚌埠医学院学报,2018,43(5):592-595.[16]魏熙胤,张翠翠,臧凤琳,等.肺癌患者外周血淋巴细胞亚群与预后的关系[J].中国肿瘤临床,2014,41(6):390-393.[17]魏智民,张维强,高峰,等.淋巴细胞亚群对晚期非小细胞肺癌患者化疗效果及远期生存的影响[J].中国医学科学院学报,2017,39(3):371-376.[18]王勇.晚期恶性肿瘤患者化疗前后外周血T淋巴细胞亚群监测及临床意义[J].蚌埠医学院学报,2016,41(11):1452-1454.[19]Li K,Zhang Q,Zhang Y,et al.T-cell-associated cellular immunotherapy for lung cancer[J].J Cancer Res Clin Oncol,2015,141(7):1249-1258.[20]高斌成.非小细胞肺癌外周血CD3+、CD4+等T淋巴细胞亚群水平及意义[J].临床肺科杂志,2018,23(1):138-141.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]袁 康,谭 伟.多层螺旋CT用于小细胞肺癌与肺鳞癌的鉴别诊断价值分析[J].医学信息,2018,31(16):148.[doi:10.3969/j.issn.1006-1959.2018.16.047]
　YUAN Kang,TAN Wei.Value of Multi-slice Spiral CT in Differential Diagnosis of Small Cell Lung Cancer and Lung Squamous Cell Carcinoma[J].Journal of Medical Information,2018,31(18):148.[doi:10.3969/j.issn.1006-1959.2018.16.047]
[4]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(18):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[5]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(18):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[6]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(18):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[7]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(18):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[8]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[9]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(18):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[10]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(18):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]

更新日期/Last Update: 1900-01-01